Nombre del producto:4-chloroquinazoline

IUPAC Name:4-chloroquinazoline

CAS:5190-68-1
Fórmula molecular:C8H5ClN2
Pureza:97%
Número de catálogo:CM114974
Peso molecular:164.59

Unidad de embalaje Stock disponible Precio($) Cantidad
CM114974-5g in stock Žř
CM114974-10g in stock ĜǭŽ
CM114974-25g in stock ǭƩŁ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :5190-68-1
Fórmula molecular:C8H5ClN2
Punto de fusión:-
Código de sonrisas:ClC1=C2C=CC=CC2=NC=N1
Densidad:
Número de catálogo:CM114974
Peso molecular:164.59
Punto de ebullición:281.0±13.0°C at 760 mmHg
Nº Mdl:MFCD00228682
Almacenamiento:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.